XCOPRI

This brand name is authorized in United States. It is also authorized in Canada, Israel.

Active ingredients

The drug XCOPRI contains one active pharmaceutical ingredient (API):

1	Cenobamate UNII P85X70RZWS - CENOBAMATE
	Cenobamate is a small molecule with a dual mechanism of action. It is a positive allosteric modulator of subtypes of the γ-aminobutyric acid (GABAA) ion channel, that does not bind to the benzodiazepine binding site. Cenobamate has also been shown to reduce repetitive neuronal firing by enhancing the inactivation of sodium channels and by inhibiting the persistent component of the sodium current.
	Read more about Cenobamate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XCOPRI Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N03AX25		N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics
Discover more medicines within N03AX25

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02538652, 02538660, 02538725, 02538733, 02538741, 02538768, 02538776, 02538784, 02538792, 02538806, 02538814
IL	מִשְׂרַד הַבְּרִיאוּת	9271, 9272, 9274, 9275, 9276
US	FDA, National Drug Code	71699-050, 71699-100, 71699-150, 71699-200